Status:
COMPLETED
Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
Lead Sponsor:
Alcon Research
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
12+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.
Eligibility Criteria
Inclusion
- 12 years of age or older.
- History (within the past 24 months) of allergic conjunctivitis.
- Active signs and symptoms of ocular allergies.
- Ocular health within normal limits, as determined by the investigator or subinvestigator.
- Willing to avoid contact lens wear each study visit immediately prior to study medication instillation and for 10 minutes after instillation of study drug.
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Contraindications or hypersensitivity to study medication or its components.
- One sighted eye or not correctable to 0.6 logMAR or better in both eyes at the screening visit.
- Known history of recurrent corneal erosion syndrome.
- Ocular trauma or surgical intervention within 6 months prior to Visit 1.
- Participation in any other investigational study within 30 days before Visit 1.
- Pregnant or nursing.
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
215 Patients enrolled
Trial Details
Trial ID
NCT01159769
Start Date
June 1 2010
End Date
August 1 2010
Last Update
April 3 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.